Maintenance of remission in Crohn's disease: Current and emerging therapeutic options

Drugs

Volumn 64, Issue 10, 2004, Pages 1069-1089

  Brookes, Matthew J ^a,b   Green, Jonathon R B ^a  

^a CITY GENERAL HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTIINFECTIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; HUMAN GROWTH HORMONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; ONERCEPT; ORNIDAZOLE; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CROHN DISEASE; DIABETES MELLITUS; DIARRHEA; DISEASE ACTIVITY; DISEASE TRANSMISSION; GASTROINTESTINAL TOXICITY; HEADACHE; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; IMMUNOPATHOGENESIS; INFECTION; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LIVER DISEASE; NAUSEA; NEUROPATHY; NONHUMAN; NUTRITION; OBSTRUCTIVE JAUNDICE; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PAIN; PANCREATITIS; PNEUMONIA; REMISSION; REVIEW; SIDE EFFECT; SMOKING CESSATION; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MESALAMINE; NUTRITION THERAPY; PREGNANCY; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; SMOKING CESSATION;

EID: 2942612457     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464100-00004     Document Type: Review

References (161)

1. Kirsner JB. Non-specific inflammatory bowel disease (ulcerative colitis and Crohn's disease) after 100 years: what next? Ital J Gastroenterol Hepatol 1999; 31: 651-8
2. Best WR, Becktel LM, Singleton JW, et al. Development of a Crohn's disease activity index. Gastroenterology 1976; 70: 439-44
3. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease: results of a prospective longitudinal study. J Clin Gastroenterol 1998; 1084: 401-5
4. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 34: 1437-9
5. Biancone L, Fantini M, Tosti C, et al. Fecal alpha-1-antitrypsin as a marker of clinical relapse in patients with Crohn's disease of the distal ileum. Eur J Gastroenterol Hepatol 2003; 15: 261-6
6. Tibble JA, Sightorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22
7. Ogura Y, Bonen DK, Inohara N, et al. A frame shift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6
8. Hampe J, Cuthbert A, Croucher PJP, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1925-8
9. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603
10. Chamaillard M, Philpott D, Giradin SE. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A 2003; 100 (6): 3455-60
11. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor KB in inflammatory bowel disease. Gut 1998; 42: 477-84
12. Singh B, Read S, Asseman C, et al. Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001; 182: 190-200
13. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295-302
14. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/ Bax mucosal imbalance. J Immunol 1999; 163: 1081-90
15. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999; 116: 557-65
16. Reimund LM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-α, interleukin-1β, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39: 684-9
17. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocots from patients with chronic active Crohn's disease by using a capase-dependant pathway. Gastroenterology 2001; 121: 1145-57
18. Van Deventer SJH. Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001; 121: 1242-6
19. Papadakis KA, Targan SR. Tumour necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-57
20. Burns RC, Rivera-Nieves J, Moskaluk CA, et al. Antibody blockade if ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 2001; 121: 1428-36
21. Schuppan D, Hahn EG. MMPs in the gut: inflammation hits the matrix. Gut 2000; 47: 12-4
22. Pender SL, Tickle SP, Docherty AJ, et al. A major role of matrix metalloproteinases in T cell injury in the gut. J Immunol 1997; 158: 1582-90
23. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5
24. Gross V, Andus T, Caesar I, et al. Oral pH-dependant budesonide versus 6-methylprednisilone in active Crohn's disease: German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996; 8: 905-9
25. Kane SV, Schoenfeld P, Sandborn WJ, et al. Systematic review: the effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002; 16 (8): 1509-17
26. Makins RJ, Cowen RE. 5-Amino-salicylate in the management of inflammatory bowel disease. Colorectal Dis 2001; 3 (4): 218-22
27. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15: 1699-708
28. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7
29. Vandell AG, DiPiro JT. Low dosage methotrexate for the treatment and maintenance of remission in patients with inflammatory bowel disease. Pharmacotherapy 2002; 22 (5): 613-20
30. Targan SR, Hanauer SB, Van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor-α for Crohn's disease. N Engl J Med 1997; 337: 1029-35
31. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405
32. Ricart E, Pannacione R, Leftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 722-9
33. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000; 95: 3490-7
34. Camma C, Giunta M, Rosselli M, et al. 5-Aminosalicyclic acid in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 1465-73
35. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of post-operative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000; 118: 264-73
36. Clemett D, Markham A. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 2000; 59 (4): 929-56
37. Pearson DC, May GA, Pick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2: CD2000067
38. Cuillerier E, Lemann M, Bouhnik Y, et al. Azathioprine for prevention of post-operative recurrence in Crohn's disease: a retrospective study. Eur J Gastroenterol Hepatol 2001; 13(11): 1291-6
39. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term randomised double-blind study. N Engl J Med 1980; 302: 981-7
40. Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000; 45 (9): 1810-3
41. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000; 14: 1561-5
42. Feagan BG, Fedorak RN, Irving EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. Gastroenterology 1999; 28: 297-321
43. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomised, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 2203-9
44. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomised, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46: 1724-9
45. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term safety and toxicity. Am J Gastroenterol 2000; 95: 1730-4
46. Baron TH, Truss CD, Elson CO. Low dose methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993; 38: 1851-6
47. Vandeputte L, D'Haens G, Baert F, et al. Methotrexate in refractory Crohn's disease. Inflamm Bowel Dis 1999; 5: 11-5
48. Chong RY, Hanauer SG, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001; 15: 35-44
49. Rutgeerts P, D'Haens ER, Targan SR, et al. Efficacy and safety of retreatment with anti-tumour necrosis factor antibody to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9
50. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002; 359: 1541-9
51. Summers RW, Switz DM, Sesssions Jr JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69
52. Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol 1997; 92: 559-66
53. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn's disease (Cochrane Review). Cochrane Database Syst Rev 2001; 1: CD000301
54. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996; 110 (1): 45-51
55. Papi C, Luchetti R, Gili L, et al. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther 2000; 14 (11): 1419-28
56. Stuck AE, Minder CE, Frey EJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954-63
57. Gurwitz JH, Bonn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycaemic therapy. Arch Intern Med 1994; 154: 97-101
58. Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 878-83
59. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86 (2): 249-66
60. Lennard-Jones JE. Sulphasalazine in asymptomatic Crohn's disease: a multicentre trial. Gut 1977; 18: 69-72
61. Wenckert A, Kristensen M, Eklund AE, et al. The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primary resected patients with Crohn's disease: a controlled double-blind trial. Scand J Gastroenterol 1978; 13: 161-7
62. Bergman L, Krause U. Postoperative treatment with corticosteroid and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. Scand J Gastroenterol 1976; 11: 651-6
63. Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology 1996; 110: 688-93
64. Sutherland LR. Prevention of relapse of Crohn's disease. Inflamm Bowel Dis 2000; 6: 321-8
65. Chan GL, Erdmann GR, Gruber SA, et al. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in transplant patients. J Clin Pharmacol 1990; 30: 358-63
66. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-39
67. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16 (10): 1743-50
68. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62
69. Bach JF. The mode of action of immunosuppressive agents. Front Biol 1975; 41: 1-374
70. Campbell AC, Skinner JM, Maclennan IF, et al. Immunosuppression in the treatment of inflammatory bowel disease. II: the effect of azathioprine on lymphoid cell populations in a double blind trial in ulcerative colitis. Clin Exp Immunol 1976; 24: 249-58
71. Szawlowski PW, Al Safi SA, Dooley T, et al. Azathioprine suppresses the mixed lymphocyte reaction of patients with Lesch-Nyhan syndrome. Br J Clin Pharmacol 1985; 20: 489-91
72. Campbell AC, Skinner JM, Hersey P, et al. Immunosuppression in the treatment of inflammatory bowel disease. I: changes in lymphoid sub-populations in the blood and rectal mucosa following cessation of treatment with azathioprine. Clin Exp Immunol 1974; 16: 521-33
73. Kinlen LJ, Sheil AG, Peto J, et al. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. BMJ 1979; 2: 1461-6
74. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-52
75. Fraser AF, Orchard TR, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine: a 30-year study. Gut 2002; 50 (4): 485-9
76. Candy S, Wright J, Gerber M, et al. A controlled double-blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-8
77. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-9
78. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatological patients. Arch Dermatol 1995; 131: 193-7
79. Snow JL, Gibson LE. A pharmacogenetic basis for the safe use of azathioprine and other thiopurine drugs in dermatologie patients. J Am Acad Dermatol 1995; 32: 114-6
80. Cuffouri C, Hunt S, Bayless T. Utilisation of erythroctye 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6
81. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyl transferase activity with azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70
82. Modigliani R. Immunosuppressors for inflammatory bowel disease: how long is long enough? Inflamm Bowel Dis 2000; 6: 251-7
83. Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16 (4): 693-7
84. Moshkowitz M, Oren R, Tishler M, et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1997; 11: 569-73
85. Rampton DS. Methotrexate in Crohn's disease. Gut 2001; 48: 790-1
86. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 3150-6
87. Connell WR. Safety of drug therapy in pregnant and nursing women. Inflamm Bowel Dis 1996; 2: 33-47
88. Siegal SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vivo and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995; 7: 251-9
89. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Cytokine 1995; 7: 15-25
90. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123 (3): 707-13
91. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumour necrosis factor (Infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97 (9): 2357-63
92. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, et al. High serum tumour necrosis factor alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002; 97 (9): 2350-6
93. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastronterol Hepatol 2002; 17: 5176-85
94. Keane J, Gershan S, Wise RP. Tuberculosis associated with infliximab, a tumour necrosis factor-α neutralizing agent. N Engl J Med 2001; 345: 1098-104
95. Bebb JR, Logan RP. Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma? Aliment Pharmacol Ther 2001; 15 (12): 1843-9
96. Hanauer SB. Review article: safety of infliximab in clinical trial. Aliment Pharmacol Ther 1999; 13 Suppl. 4: 16-22
97. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002; 97 (12): 2962-72
98. MacPherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996; 38: 365-75
99. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics and ecotherapeutics. Gastroenterology 2001; 120: 622-35
100. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32 (9): 1071-5
101. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998; 12: 53-6
102. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328-32
103. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-21
104. Rutgeerts P, Van Assche G, D'Haens G, et al. Ornidazole for prophylaxis of post operative Crohn's disease: final results of a double blind placebo-controlled trial [abstract]. Gastroenterology 2002; 122: A60
105. Cosnes J, Carbonnel F, Carrat F, et al. Respective effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther 1999; 13: 1403-11
106. Lindberg E, Jarnerot G, Huitfeldt B. Smoking in Crohn's disease: effect on localisation and clinical course. Gut 1992; 33: 779-82
107. Russel MG, Nieman FH, Bergers JM, et al. Cigarette smoking and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol 1996; 8: 1075-81
108. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of smoking on long-term course of Crohn's disease. Gastroenterology 1996; 110: 424-31
109. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastrenterology 1994; 106: 643-8
110. Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001; 120: 1093-9
111. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841-54
112. Heuschkel RB, Menache CC, Megerian JT, et al. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000; 31: 8-15
113. Pearson M, Teahon K, Levi AJ, et al. Food intolerance and Crohn's disease. Gut 1993; 34: 783-7
114. Riordan AM, Hunter JO, Cowan RE, et al. Treatment of active Crohn's disease by exclusion diet: East Anglian multicentre controlled trial. Lancet 1993; 342: 1131-4
115. Verma S, Kirkwood B, Brown S, et al. Oral nutrition supplementation is effective in the maintenance of remission in Crohn's disease. Dig Liver Dis 2000; 32: 769-74
116. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996; 334: 1557-60
117. Lamah M, Scott HJ. Inflammatory bowel disease during pregnancy. Int J Colorectal Dis 2002; 17: 216-22
118. Norgard B, Fonager K, Pederson L, et al. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut 2003; 52 (2): 243-7
119. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynaecol 1993; 82: 348-52
120. Subhani JM, Hamiliton MI. Review article: the management of inflammatory bowel disease during pregnancy. Aliment Pharmacol Ther 1998; 12: 1039-52
121. Antoni CE, Furst DE, Manger B, et al. Outcome of pregnancy in women receiving Remicade® (infliximab) for the treatment of Crohn's disease or rheumatoid arthritis [abstract]. Arthritis Rheum 2001; 44 Suppl. 9: S152
122. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomised, double-blind, placebo-controlled trial. Gastroenterology 2001; 121 (5): 1242-6
123. Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomised, open-label, pilot study. Aliment Pharmacol Ther 2003; 17 (2): 185-92
124. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP-571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997; 349: 521-4
125. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP-571) for active Crohn's disease: a randomized double-blind placebo-controlled. Gastroenterology 2001; 120: 1130-8
126. Kuhn R, Lohler J, Rennick DM, et al. Interleukin-10-deficient mice develop chronic enterolcolitis. Cell 1993; 75 (2): 263-74
127. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996; 98 (4): 1010-20
128. Davidson NJ, Hudak SA, Lesley RE, et al. TL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998; 161 (6): 3143-9
129. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190 (7): 995-1005
130. Van-Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in a steroid-refractory Crohn's disease. Gastroenterology 1997; 113 (2): 383-9
131. Schreiber S, Fedorak RN, Nielson OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology 2000; 119: 1461-72
132. Colombel JF, Rutgeerts P, Malchow HA, et al. Interleukin 10 in the prevention of postoperative recurrence of Crohn's disease. Gut 2001; 49: 42-6
133. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2002; 348 (1): 24-32
134. Gordon FH, Lai CWY, Hamilton MI, et al. A randomized placebo-controlled trial of humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 2001; 121: 268-74
135. Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel disease. Gut 1995; 36: 724-30
136. Yacyshyn BR, Bowen Yacyshyn MB, Jeweils L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114: 1133-42
137. Yacyshyn BR, Chey WY, Goff J, et al. Double-blind, placebo-controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS-2302) in active steroid-dependant Crohn's disease. Gut 2002; 51 (1): 30-6
138. Yacyshyn BR, Barish C, Goff J, et al. Dose ranging pharmacokinetics trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002; 16 (10): 1761-70
139. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002; 360: 1478-80
140. Sands BE, Winston BD, Salzberg B, et al. Randomized, controlled trial of recombinant human interleukin 11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002; 16 (3): 399-406
141. Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000; 342 (22): 1633-7
142. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969; 113: 515-24
143. Miehsler W, Reinisch W, Moser G, et al. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol 2001; 96 (3): 782-7
144. Hassard PV, Vasiliauskas EA, Kam LY, et al. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis 2000; 6 (1): 16-20
145. Strange EF, Modgiliani R, Pena AS, et al. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. Gastroenterology 1995; 109: 774-82
146. Jewell DP, Lennard-Jones JE, and The Cyclosporin Study Group of Great Britain and Ireland. Oral cyclosporin for chronic active Crohn's disease: a multi-centre controlled trial. Eur J Gastroenterol Hepatol 1994; 6: 499-505
147. Feagan BG, McDonald JW, Rochon J, et al. Low dose cyclosporin for the treatment of Crohn's disease: the Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994; 330: 1846-51
148. Ierardi E, Principi M, Pisani RF, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001; 15 (3): 371-7
149. Casson DH, Eltumi M, Tomlin S, et al. Topical tacrolimus may be effective in the treatment of oral and perianal Crohn's disease. Gut 2000; 47: 436-40
150. Moreira A, Sampaio E, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumour necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80
151. Wettstein A, Meagher A. Thalidomide in Crohn's disease. Lancet 1997; 350: 1445-6
152. Fishman S, Feins N, D'Amato R, et al. Long-term remission of Crohn's disease treated with thalidomide: a seminal case report. Angiogenesis 2000; 3: 29-36
153. Vasiliauskas EA, Kam L, Abreu-Martin M, et al. An open-label study of low dose thalidomide in chronically active, steroid-dependant Crohn's disease. Gastroenterology 1999; 117: 1278-87
154. Ethrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271-7
155. Sabate JM, Villarejo J, Lemann M, et al. An open-label study of thalidomide for maintenance therapy in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002; 16 (6): 1117-24
156. Lilly DM, Stillwell RH. Probiotics: growth promoting factors produced by microorganisms. Science 1965; 47: 747-8
157. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics: approaching a definition. Am J Clin Nutr 2001 Feb; 73 (2 Suppl.): 361S-4S
158. Malchow HA. Crohn's disease and Escherichia coli: a new approach in therapy to maintain remission of colonie Crohn's disease? J Clin Gastroenterol 1997; 25: 653-8
159. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45 (7): 1462-4
160. Prantera C, Scribano ML, Galasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn' s disease: a randomized controlled trial with Lactobacillus GG. Gut 2002; 51: 405-9
161. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post operative recurrence of Crohn's disease: a randomized controlled trial vs mesalazine [abstract]. Gastroenterology 2000; 118: A781